Jonathan Schisler, MS, PhD, led research showing that limiting the activity of a mutant CHIP protein could decrease symptom severity for people with cerebral ataxia, a debilitating disease of the nervous system.
Jonathan Schisler, MS, PhD, led research showing that limiting the activity of a mutant CHIP protein could decrease symptom severity for people with cerebral ataxia, a debilitating disease of the nervous system.